Efficacy of oral casopitant mesylate, a novel neurokinin-1 receptor antagonist, with intravenous ondansetron HCl in the prevention of postoperative nausea and vomiting (PONV) in high-risk patients

2006 ◽  
Vol 23 (Supplement 37) ◽  
pp. 159-160 ◽  
Author(s):  
N. Singla ◽  
F. Chung ◽  
S. Singla ◽  
A. Grenier ◽  
D. Kutsogiannis ◽  
...  
Keyword(s):  
High Risk ◽  
Receptor Antagonist ◽  
Postoperative Nausea ◽  
Postoperative Nausea And Vomiting ◽  
Nausea And Vomiting ◽  
Neurokinin 1 Receptor ◽  
High Risk Patients ◽  
Risk Patients ◽  
Neurokinin 1

scholarly journals A Comparison of Fosaprepitant and Ondansetron for Preventing Postoperative Nausea and Vomiting in Moderate to High Risk Patients: A Retrospective Database Analysis

2017 ◽  
Vol 2017 ◽  
pp. 1-5 ◽  
Author(s):  
Chiaki Murakami ◽  
Nami Kakuta ◽  
Katsuyoshi Kume ◽  
Yoko Sakai ◽  
Asuka Kasai ◽  
...  
Keyword(s):  
General Anesthesia ◽  
Receptor Antagonist ◽  
Postoperative Nausea ◽  
Postoperative Nausea And Vomiting ◽  
Complete Response ◽  
Nausea And Vomiting ◽  
Nk1 Receptor Antagonist ◽  
Risk Patients ◽  
Neurokinin 1 ◽  
Type 3

Postoperative nausea and vomiting (PONV) occur in 30–50% of patients undergoing general anesthesia and in 70–80% of high PONV risk patients. In this study, we investigated the efficacy of fosaprepitant, a neurokinin-1 (NK1) receptor antagonist, compared to ondansetron, a selective 5-hydroxytryptamine type 3 (5-HT3) receptor antagonist, in moderate to high PONV risk patients from our previous randomized controlled trials. Patients (171 patients from 4 pooled studies) with the Apfel simplified score ≥ 2 and undergoing general anesthesia were randomly allocated to receive intravenous fosaprepitant 150 mg (NK1 group, n=82) and intravenous ondansetron 4 mg (ONS group, n=89) before induction of anesthesia. Incidence of vomiting was significantly lower in the NK1 group compared to the ONS group 0–2, 0–24, and 0–48 hours after surgery (2 versus 17%, 2 versus 28%, and 2 versus 29%, resp.). However, no significant differences in PONV, complete response, rescue antiemetic use, and nausea score were observed between groups 0–48 hours after surgery. In moderate to high PONV risk patients, fosaprepitant decreased the incidence of vomiting and was superior to ondansetron in preventing postoperative vomiting 0–48 hours after surgery.

Postoperative nausea and vomiting

2020 ◽  
Vol 81 (6) ◽  
pp. 1-3
Author(s):  
Jonathan Barnes
Keyword(s):  
High Risk ◽  
Postoperative Nausea ◽  
Postoperative Nausea And Vomiting ◽  
Nausea And Vomiting ◽  
High Risk Patients ◽  
Risk Patients

Nausea and vomiting after surgery is common and can be both unpleasant and lead to an array of other adverse patient effects. Identification of high-risk patients and targeted prophylaxis can reduce its incidence and associated complications.

Sign in / Sign up

Export Citation Format

Share Document